Nimbus Therapeutics
Biotechnology company pioneering structure-based drug design using computational approaches to discover small molecule medicines for immunology, oncology, and metabolic diseases.
Notes
Nimbus Therapeutics is a biotechnology company that uses structure-based drug design and computational approaches to discover and develop small molecule medicines. The company has built multiple drug programs targeting challenging targets in immunology, oncology, and metabolic diseases.
In 2022, Nimbus achieved a landmark $4 billion deal with Takeda Pharmaceutical for its TYK2 inhibitor program (NDI-034858), which became TAK-279. This was one of the largest acquisitions of a single drug program in biotech history, with $4 billion upfront and up to $2 billion in potential milestones.
Team
- Jeb Keiper - Chief Executive Officer
- LinkedIn: linkedin.com/in/jebkeiper
- Don Nicholson, Ph.D. - President & Chief Scientific Officer
- Rosana Kapeller, M.D., Ph.D. - Co-Founder (former CSO)
Additional Research Findings
- Founded in 2009 in Cambridge, Massachusetts
- Pioneer in computational structure-based drug discovery
- $4 billion deal with Takeda for TYK2 inhibitor (NDI-034858/TAK-279) in 2022
- Additional pipeline programs include HPK1 for oncology and ACC for metabolic disease
- Backed by Atlas Venture, SROne, and other top-tier investors
- Known for successful "asset-centric" subsidiary model
- The Takeda deal validated Nimbus's computational drug discovery approach